Cargando…
The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression
The Farnesoid X receptor (FXR) regulates bile salt, glucose and cholesterol homeostasis by binding to DNA response elements, thereby activating gene expression (direct transactivation). FXR also inhibits the immune response via tethering to NF-κB (tethering transrepression). FXR activation therefore...
Autores principales: | Bijsmans, Ingrid T. G. W., Guercini, Chiara, Ramos Pittol, José M., Omta, Wienand, Milona, Alexandra, Lelieveld, Daphne, Egan, David A., Pellicciari, Roberto, Gioiello, Antimo, van Mil, Saskia W. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572934/ https://www.ncbi.nlm.nih.gov/pubmed/26369990 http://dx.doi.org/10.1038/srep14086 |
Ejemplares similares
-
Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis
por: Aneeza, W. Hamizan, et al.
Publicado: (2013) -
Mometasone furoate in the management of asthma: a review
por: Tan, Ricardo A, et al.
Publicado: (2008) -
Effectiveness of 0.1% mometasone furoate under hydrocolloid dressing versus 0.1% mometasone furoate in patients with lichen simplex chronicus
por: Lo, Hiu Lai, et al.
Publicado: (2023) -
Mometasone furoate nasal spray: a systematic review
por: Passali, Desiderio, et al.
Publicado: (2016) -
Mometasone furoate is not superior to saline for chronic rhinitis in the elderly
por: Carvalho, Victor, et al.
Publicado: (2019)